Losmapimod
Facioscapulohumeral Muscular Dystrophy (FSHD)
Key Facts
Indication
Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase
Phase 3
Status
Active (Top-line data reported)
Company
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biotech company with a mission to develop small molecule therapies that treat the root cause of genetically defined rare diseases by modulating gene expression. Its core achievement is the development of a proprietary functional genomics platform that identifies master regulator proteins to create targeted treatments. The company's strategy focuses on high-unmet-need disorders with clear genetic drivers, such as FSHD and sickle cell disease, leveraging regulatory pathways for rare diseases. Fulcrum's lead asset, losmapimod for FSHD, has completed Phase 3 trials, positioning the company for a potential near-term regulatory filing and commercialization.
View full company profileTherapeutic Areas
Other Facioscapulohumeral Muscular Dystrophy (FSHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DX5057 | Altay Therapeutics | Preclinical |
| Restem-L | Restem | Unknown |
| AOC 1020 | Avidity Biosciences | Phase 1/2 |
| DYNE-301 | Dyne Therapeutics | Phase 1/2 |